Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or metastatic cancer.
Mattia Belloni
Advertisement
Articles by Mattia Belloni
Advertisement
Latest Updated Articles
Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS EndpointsPublished: June 23rd 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
2
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
3
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
4
Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity
5
